GT Medical Technologies Announces $16 Million Financing to Expand Availability of Targeted Therapy for Patients with Recurrent Brain Tumors
GT Medical Technologies Announces $16 Million Financing to Expand Availability of Targeted Therapy for Patients with Recurrent Brain Tumors
11/23/20, 12:34 PM
Location
tempeMoney raised
$16 million
GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced it has raised $16 million in a Series B financing led by MVM Partners with participation from existing investors MedTech Venture Partners and BlueStone Venture Partners. Funds from the round will support the expanded commercialization of GammaTile® Therapy, an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for patients with brain tumors.
Company Info
Location
tempe, arizona, united states
Additional Info
Driven to overcome the limitations of the current standard of care for brain tumors, a team of brain tumor specialists joined forces and formed GT Medical Technologies with the purpose of improving the lives of patients with brain tumors. GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent and newly diagnosed malignant brain tumors. Patients receive GammaTile at the time of their tumor removal surgery which, in contrast to traditional radiation therapy, requires no additional trips to the hospital or clinic for radiation therapy. GammaTile is available in top brain tumor centers across the United States. For more information or to find a GammaTile center near you, visit https://www.gtmedtech.com/ and follow @GTMedTech on Twitter and LinkedIn.